drugset / Trial / NCT01222572

Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer

NCT01222572 ↗

Non-randomizedSingle-groupOpen-labelTreatment

Summary

In this research study the investigators are looking for the highest dose of a stereotactic radiation boost that can be given safely. Because stereotactic radiation is so precise, the investigators are testing whether it can be used to increase the dose to the primary tumor without significantly increasing the side effects the participant experiences; the goal is to improve the likelihood of killing the tumor.

Timeline

Start
2010-12
Primary completion
2012-03
Completion
2012-10

Outcome

Outcome not reported

Stopped (Enrollment): “Slow accrual due to restrictive eligibility criteria”

Drugs

EvaluationDrugModalityDoseRoute
Background Cisplatin Other / unclassified 50 mg/m2 —
Background Etoposide Small molecule 50 mg/m2 —